Aspart and lispro insulin, is there any difference when used with an insulin pump treatment?

Abstract 

The DCC and the EDIC study studies showed the significance of intensive insulin treatment in reducing blood glucose levels and delaying the onset/progression of cardiovascular disease and microvascular complications. To minimise cardiovascular risk it is necessary to maintain a daytime glucose profile without significant variability. Short or rapid-acting insulin analogues allow a better postprandial glucose control and reduce hypoglycaemic risk. Clinical trials with insulin aspart and insulin lispro have demonstrated improved postprandial glucose control in comparison with human insulin, however, studies directly comparing the activities of insulin aspart and insulin lispro present inconsistent findings, and very few data are now available comparing aspart and lispro in an insulin pump treatment. In order to compare the effect of insulin aspart vs insulin lispro on daytime glucose stability, in patients with Type 1 diabetes mellitus during a CSII treatments, we designed a randomised, cross-over group trial of aspart vs lispro on daytime glycaemic variability evaluated with Continuous Glucose Monitoring System (CGMS). The present report presents the procedures, the baseline demographic and biomedical characteristics and describes the major outcome variables that were measured at entry.

Keywords:  Continuous subcutaneous insulin infusion , Insulin pump , Insulin analogues , Type 1 diabetes , HbAlc

No full text is available. To read the body of this article, please view the PDF online.